Current molecular genetic markers of breast cancer
https://doi.org/10.17650/1994-4098-2011-0-1-19-28
Abstract
The paper concerns the molecular and genetic markers of breast cancer (BC). For practice use it is expedient to limit a BC expression analysis panel with the VEGFR 1, VEGFR 2, VEGF 121, PDGFR, mTOR, Her-2/neu, Ki-67, BRCA 1, ESR 1, Ostp, BIRC 2 and BIRC 5 genes to accelerate the test and reduce its cost and to simplify interpretation by physicians. These 12 genes carry basic information that is required to choose and predict a chemotherapy response and that serves as its prognostic markers, by indicating the potential therapeutic targets.
About the Authors
N. V. Apanovich
Molecular Genetics Research Center, Russian Academy of Medical Sciences; N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
V. P. Shubin
Molecular Genetics Research Center, Russian Academy of Medical Sciences; N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
A. A. Korotayeva
Molecular Genetics Research Center, Russian Academy of Medical Sciences; N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
A. S. Bavykin
Molecular Genetics Research Center, Russian Academy of Medical Sciences; N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
E. A. Kim
МГНЦ РАМН; РОНЦ им. Н.Н. Блохина РАМН; 1-й МГМУ им. И.М. Сеченова
Russian Federation
Russian Federation
A. D. Zakiryakhodzhayev
Molecular Genetics Research Center, Russian Academy of Medical Sciences; N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
V. P. Letyagin
Molecular Genetics Research Center, Russian Academy of Medical Sciences; N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
I. V. Vysotskaya
Molecular Genetics Research Center, Russian Academy of Medical Sciences; N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
A. V. Karpukhin
Molecular Genetics Research Center, Russian Academy of Medical Sciences; N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Pankaj T., Dejan M., Fumitake K. et al. Classical and novel prognostic markers for breast cancer and their clinical significance. Clin Med Insights Oncol — 2010;15–34.
2. Jensen E.V., Jordan V.C. The estrogen receptor: a model for molecular medicine. Clin Cancer Res 2003;9:1980.
3. Margeli M., Cirauqui B., Castella E. et al. The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer. PLoS One 2010;9499.
4. Anders C.K., Carey L.A. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 2009;2:73–81.
5. Schlotter C.M., Vogt U., Allgayer H. et al. Molecular targeted therapies for breast cancer treatment. Breast Cancer Res 2008;10:211.
6. Hobday T.J., Perez E.A. Molecularly targeted therapies for breast cancer. Cancer Control 2005;12(2):73–81.
7. Chu D., Lu J. Novel therapies in breast cancer: what is new from ASCO 2008. J Hematol Oncol 2008.
8. Gustafsson A., Martuszewska D., Johansson M. et al. Differential expression
9. of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res 2009;15:4742–9.
10. Taneja P., Maglic D., Kai F. et al. Classical and novel prognostic markers for breast cancer and their clinical significance. Clinical Medicine Insights. Oncology 2010;4:15–34.
11. Urruticoechea A., Smith I.E., Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23(28):7212–20.
12. Zakhartseva L.M., Gorovenko N.G., Podolskaya S.V. et al. Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations. Exp Oncol 2009;31:174–8.
13. Stebbing J., Ellis P., Tutt A. PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers. Future Oncol 2010;485–6.
14. Rodrigues L.R., Teixeira J.A., Schmitt F.L. et al. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomark Prev 2007;1087– 97.
15. Shevde L.A., Das S., Clark D.W., Samant R.S. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med 2010;71–81.
16. McManus D.C., Lefebvre C.A., Cherton-Horvat G. et al. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse hemotherapeutics. Oncogene 2004;23:8105–17.
17. Fandy T.E., Shankar S., Srivastava R.K. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer 2008;7:60–9.
18. Hunter A.M., LaCasse E.C., Korneluk R.G. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007;12:1543–68.
19. Day T.W., Huang S., Safa A.R. c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9- dependent apoptosis in breast cancer cells. Biochem Pharmacol 2008;76(12):1694–704.
20. Day T.W., Sinn A.L. c-FLIP gene silencing eliminates tumor cells in breast cancer xenografts without affecting stromal cells. Anticancer Res 2009;29(10):3883–6.
21. De Ligio J.T., Velkova A., Zorio D.A. et al. Can the status of the Breast and Ovarian Cancer Susceptibility Gene 1 product (BRCA 1) predict response to taxane-based cancer therapy? Anticancer Agents Med Chem 2009;543–9.
22. Song L., Xu Z., Zhang C. et al. Up- regulation of the HSP72 by Foxa1 in MCF-7 human breast cancer cell line. Biochem Biophys Res Commun 2009;386(1):30–4.
23. Foster F.M., Owens T.W., Tanianis- Hughes J. et al. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res 2009;11(3):1–13.
24. Palmieri C., Cheng G.J., Saji S. et al. Estrogen receptor beta in breast cancer. Endocr Relat Cancer 2002;9:1–13.
25. Sommer S., Fuqua S.A. Estrogen receptor and breast cancer. Semin Cancer Biol 2001;11:339–52.
26. Tanaka K., Iwamoto S., Gon G. et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127–34.
Review
For citations:
Apanovich N.V., Shubin V.P., Korotayeva A.A., Bavykin A.S., Kim E.A., Zakiryakhodzhayev A.D., Letyagin V.P., Vysotskaya I.V., Karpukhin A.V. Current molecular genetic markers of breast cancer. Tumors of female reproductive system. 2011;(1):19-28. (In Russ.) https://doi.org/10.17650/1994-4098-2011-0-1-19-28
Views:
563
Email this article 